| Market Cap | ₹15,138Cr |
| ROE | 17.79% |
| P/E Ratio(TTM) | 9.85 |
| EPS(TTM) | 85.79 |
| P/B Ratio | 1.75 |
| Dividend Yield | 0.71% |
| Industry P/E | 32.56 |
| Book Value | 482.93 |
| Debt to Equity | 0.03 |
| Face Value | 2 |
| Managing Director | Rajeev Nannapaneni |
| Founded | 1981 |
| NSE Symbol | NATCOPHARM |
| FUND NAME | AUM(%) |
|---|---|
| Sundaram Small Cap Fund Direct Growth | 1.60% |
| Axis Nifty Smallcap 50 Index Fund Direct Growth | 1.08% |
| Tata Small Cap Fund Direct Growth | 0.44% |
| COMPANY | 52 WEEK | MARKET PRICE | P/E Ratio | |
|---|---|---|---|---|
| JB Chemicals & Pharmaceuticals | NA (0.00%) | 40.07 | ||
| Emcure Pharmaceuticals | NA (0.00%) | 35.82 | ||
| Wockhardt | NA (0.00%) | -451.61 | ||
| Cohance Lifesciences | NA (0.00%) | 50.91 |